Avacta losses deepen on higher R&D spend; to raise £9m

13:08 18/10/2019
StockMarketWire.com - Biotherapeutics and research reagents developer Avacta booked a deeper annual loss amid a rise in R&D spending, and said it would raise up to £9m from an equity raising.

News shares in the company would bee issued at 15p each.

Pre-tax losses for the year through July amounted to £11.1m, compared to losses of £10.4m on-year.

Revenue rose 49% to £4.1m, due to recognition of an up-front milestone payment of $2.5m from LG Chem Life Sciences.

The company's cash balance at the end of July was £6.5m, up from £5.2m on-year.

'I am very pleased to see the strong growth in Affimer reagents revenue and order intake over the reporting period,' chief executive Alastair Smith said.

'This has been driven by the growing reputation of the Affimer technology particularly in the diagnostics and pharmaceutical sectors; two markets where the company will be focusing our resources in the reagents business going forwards.'

At 1:08pm: (LON:AVCT) Avacta Group PLC share price was -0.5p at 16.5p



Story provided by StockMarketWire.com

Forex

Commodities

What the Papers Say

telegraph financial times daily mail daily express independent times
00:01 Formula One takes axe to emissions in...
source: FT.com
00:01 Burger King and Unilever launch meat-free...
source: FT.com
00:01 Alibaba aims to deliver with $16bn courier...
source: FT.com
[more ...]